Location History:
- Yongin-si, KR (2010 - 2013)
- Kyunggi-do, KR (2015)
Company Filing History:
1 out of 12 
1 out of 2 
1 out of 24 
Years Active: 2010-2015
Title: Weon Bin Im: Innovator in Oxazolidinone Derivatives
Introduction
Weon Bin Im is a notable inventor based in Yongin-si, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the development of oxazolidinone derivatives. With a total of 3 patents to his name, his work focuses on creating effective antibiotic compositions.
Latest Patents
Weon Bin Im's latest patents revolve around novel derivatives of oxazolidinone. These inventions relate to a method for producing these derivatives and pharmaceutical compositions that utilize them for antibiotic purposes. The oxazolidinone derivatives demonstrate inhibitory activity against a broad spectrum of bacteria while exhibiting lower toxicity. The prodrugs, which are prepared by reacting compounds with hydroxyl groups with amino acids or phosphates, show excellent solubility in water. Furthermore, these derivatives have potent antibacterial activity against various human and animal pathogens, including Gram-positive bacteria such as Staphylococci, Enterococci, and Streptococci, as well as anaerobic microorganisms and acid-resistant microorganisms. Consequently, the compositions that include oxazolidinone are utilized in antibiotic applications.
Career Highlights
Throughout his career, Weon Bin Im has worked with reputable companies in the pharmaceutical industry, including Dong-A Pharm Co., Ltd. and Dong-A Pharmaceuticals Co., Ltd. His experience in these organizations has contributed to his expertise in developing innovative pharmaceutical solutions.
Collaborations
Weon Bin Im has collaborated with notable colleagues such as Jae Keol Rhee and Chong Hwan Cho. These partnerships have likely enhanced his research and development efforts in the field of antibiotics.
Conclusion
Weon Bin Im is a distinguished inventor whose work on oxazolidinone derivatives has the potential to significantly impact antibiotic treatments. His innovative approach and collaborations with industry professionals underscore his commitment to advancing pharmaceutical science.